Intellia Therapeutics Announces $400M Secured Credit Facility with OrbiMed

What Happened

• Intellia Therapeutics (NTLA) filed an 8-K reporting that on September 4, 2026 it entered a five‑year senior secured Credit Agreement with OrbiMed entities acting as initial lenders and administrative agent. The facility provides up to $400 million in non-dilutive financing and matures on September 4, 2031. An initial $75 million was drawn at closing.

• The Credit Facility includes multiple optional tranche draws: an additional $75 million upon FDA approval of Intellia’s BLA for lonvoguran ziclumeran (lonvo‑z) (if before a specified date), three potential $40 million draws tied to revenue milestones for lonvo‑z, a $30 million draw tied to an equity raise target, plus an uncommitted incremental option up to $100 million subject to lender agreement. Proceeds are for working capital and general corporate purposes. Interest is payable monthly at the greater of 3.00% or one‑month SOFR plus a margin of 6.15%, and customary fees and prepayment provisions apply.

Key Details

• Facility size and term: up to $400 million, five‑year maturity (Sept 4, 2031); $75M drawn at closing.
• Optional tranches: $75M on FDA BLA approval for lonvo‑z; three $40M revenue‑based draws; $30M on equity raise; up to $100M incremental by agreement.
• Security & covenants: first‑priority security interest in substantially all assets (including IP); covenants include maintaining $50M liquidity in controlled accounts until FDA approval of lonvo‑z and other financial/negative covenants restricting additional debt, liens, material transactions, dividend payments, and certain licensing/investment activities.
• Events of default: standard defaults such as payment defaults, covenant breaches, insolvency, cross‑defaults, judgments, and change of control may accelerate repayment.

Why It Matters

• This agreement provides Intellia with significant non‑dilutive liquidity to support operations and potential commercialization of lonvo‑z without issuing equity. However, the loans are secured by the company’s assets (including intellectual property) and include financial covenants and activity restrictions that investors should monitor, especially until regulatory and revenue milestones are met. The interest formula and fees mean borrowing costs can be material; optional tranche draws depend on specific regulatory, revenue, or financing milestones.